The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
5 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,059,762 in first-year total cost, median $215,475.
Most frequent study sections
- Special Emphasis Panel[ZAI1 SAS-M (S2)]5
Most frequent institutions
- BARUCH S. BLUMBERG INSTITUTE1
- EAST TENNESSEE STATE UNIVERSITY1
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH1
- UNIVERSITY OF SOUTHERN CALIFORNIA1
- WAKE FOREST UNIVERSITY HEALTH SCIENCES1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2024 | Chemically ligated-guide RNA (lgRNA)-based CRISPR/Cas9 gene editing for elimination of hepatitis B virus cccDNA1R21AI179930-01 | GUO, JU-TAO | BARUCH S. BLUMBERG INSTITUTE, PA | $240,000 | ZAI1 |
| 2024 | Engineering exosomes for new gRNA/Cas therapeutics to eliminate HBV infection1R21AI179794-01 | YAO, ZHI Q. | EAST TENNESSEE STATE UNIVERSITY, TN | $225,000 | ZAI1 |
| 2024 | IL-1β as a novel therapeutic agent against hepatitis B virus1R21AI179734-01 | OU, J.-H. JAMES | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $215,475 | ZAI1 |
| 2024 | High throughput screening and preclinical development of HBV cccDNA inhibitors1R21AI179929-01 | GUO, HAITAO | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $198,750 | ZAI1 |
| 2024 | Toward a Curative Treatment for HBV with cccDNA-Targeting Peptide Nucleic Acids1R21AI180006-01 | GAGNON, KEITH THOMAS | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $180,537 | ZAI1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.